Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

We investigated the potential hepatotoxicity of lopinavir/ritonavir recently used in the treatment of Severe Acute Respiratory Syndrome Coronavirus. This is a retrospective cohort of critical patients in a teaching hospital: 12 treated with lopinavir/ritonavir and 30 in the standard-of-care group. Elevation occurred more frequently in patients treated with lopinavir/ritonavir (33% vs 6.7%). Caution is advised regarding the use of lopinavir/ritonavir in the most severe cases of Severe Acute Respiratory Syndrome Coronavirus.

Citation

Clementine Levy, Guillaume Lassailly, Erika Parmentier, Thibault Duburcq, Philippe Mathurin, Julien Poissy. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice. The American journal of gastroenterology. 2020 Oct;115(10):1716-1718

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32858566

View Full Text